Mortality surrogates in combined pulmonary fibrosis and emphysema.
An ZhaoEyjolfur GudmundssonNesrin MogulkocColine van MoorselTamera J CortePardeep VasudevChiara RomeiRobert ChapmanTim J M WallisEmma K DennenyTinne GoosRecep SavaşAsia AhmedChristopher J BreretonHendrik W van EsHelen JoAnnalisa De LiperiMark DuncanKatarina PontoppidanDe Sadeleer LaurensFrouke van BeekJoseph BarnettGary CrossAlex ProcterMarcel VeltkampPeter HopkinsYuben MoodleyAlessandro TalianiMagali TaylorStijn VerledenLaura TavantiMarie VermantArjun NairIain D StewartSamuel M JanesAlexandra L YoungDavid BarberDaniel C AlexanderJoanna C PorterAthol U WellsMark G JonesWim A WuytsJoseph JacobPublished in: The European respiratory journal (2023)
When assessing disease progression in IPF, DLco decline should be considered in patients with ≥10% emphysema and a ≥5% 1-year relative FVC decline threshold considered in non-CPFE IPF patients.